Skip to main content
  • Poster presentation
  • Open access
  • Published:

Diagnostic value and clinical significance of antibodies against a modified citrullinated vimentin (anti-MCV) in patients with early juvenile arthritis

Objective

To investigate the diagnostic value and clinical significance of anti-MCV in pts with early JA.

Patients and methods: 85 pts were included in the study (M/F = 36/49) in the age of 1,5–16 years (mean 8.7 ± 4.9 years). Systemic JA – 10 pts (11.8%), poly – 37 (43.5%), oligo-38 (44.7%). Duration of disease was < 6 months. We studied also 54 pts with early RA, 28 pts with undifferentiated arthritis (UA) and 14 healthy children. Anti-MCV was measured in serum by enzyme-linked immunosorbent assay (ELISA) using the cut off value of 25 U/ml. IgM RF and hsCRP-by laser-nephelometry assay on BN-100 analyser.

Results

Anti-MCV levels were elevated in 23 (27.1%) pts with early JA, in systemic – 2 (20%), poly – 11(29.7%), oligo-10 (26.3%). In pts with RF positive JA – 5 (100%), in RF negative pts- 7(17.1%) (p < 0.001). In the control groups: 34/54 (62.9%) adults with early RA (p < 0,001), 14/28 (50%) with UA (p < 0.05), none of the healthy children showed anti-MCV positivity. The median anti-MCV level in JA was 16.8 U/ml (IR: 11.5–26.4), in RF+ pts (M-834.9; IR 539.3–1149.3 U/ml) was higher than in RF-pts (M-14.5; IR:5.7–22.0 U/ml) (p < 0.001). Anti-MCV correlated with parameters of disease activity (hs CRP, ESR), with RF and anti-CCP positivity. Anti-MCV were not associated with ANA.

Conclusion

Determination of anti-MCV levels especially together with RF and anti-CCP in pts with early JA can indicate evolution JRA similar RA in adults. Anti-MCV levels correlated with common parameters of inflammation and acute phase response and may be useful to monitor disease activity.

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Salugina, S., Fedorov, E., Alexandrova, E. et al. Diagnostic value and clinical significance of antibodies against a modified citrullinated vimentin (anti-MCV) in patients with early juvenile arthritis. Pediatr Rheumatol 6 (Suppl 1), P9 (2008). https://doi.org/10.1186/1546-0096-6-S1-P9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1546-0096-6-S1-P9

Keywords